Predictive molecular markers in non-small cell lung cancer

Current Opinion in Oncology

Volumn 13, Issue 2, 2001, Pages 101-109

  Rosell, Rafael ^a   Tarón, Miquel ^a   O'Brate, Aurora ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEOXYRIBONUCLEOTIDE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; RIBONUCLEOTIDE REDUCTASE; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR; TUBULIN; TUMOR MARKER;

ARTERIOSCLEROSIS; CELL CYCLE; CHEMOSENSITIVITY; CHROMOSOME 11P; CHROMOSOME DELETION; DRUG RESISTANCE; HETEROZYGOSITY LOSS; LUNG NON SMALL CELL CANCER; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035084989     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200103000-00004     Document Type: Review

References (79)

1. The Pezcoller lecture: Cancer cell cycles revisited
2. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: A prospect for early diagnosis
3. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia
4. Genetic polymorphisms in uridine diphospho-glucoronosyltransferase 1A1 and association with breast cancer among African Americans
5. The hallmarks of cancer
6. Loss of cell cycle control allows selective microtubule-active drug-induced Bcl-2 phosphorylation and cytotoxicity in autonomous cancer cells
7. A randomized phase II trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC)
8. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: A predictor for primary tumor response and overall survival
9. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy
10. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells
11. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues
12. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: Association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins
13. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma
14. 1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-hydroxystaurosporine)
15. Expression of ERCC1 antisense IRNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair
16. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3
17. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
18. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
19. Role of E2F-1 in chemosensitivity
20. Molecular and cell biology aspects of plague
21. Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB
22. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and xenograft models is overcome by inhibition of nuclear factor-κ activation
23. KIP1 expression in estrogen receptor-negative lung cancer cells
24. WAF1 expression via Sp1-binding sites by tamoxifen in estrogen receptor-negative lung cancer cells
25. Kip1 in non-small cell lung carcinoma: A prognostic factor independent of Ras
26. Microtubule-interfering agents activate c-Jun-N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways
27. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κ is enhanced by IκBαsuper-repressor and parthenolide
28. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines
29. The NF-κ signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation
30. Inactivation of Bcl-2 by phosphorylation
31. Raf-1/bcl-2 phosphorylation: A step from microtubule damage to cell death
32. Molecular effects of paclitaxel: Myths and reality (a critical review)
33. Bcl2 translocation frequency rises with age in humans
34. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
35. Novel antisense oligonucleotide targeting surviving expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
36. INK4-mediated apoptosis in non-small cell lung cancer cells
37. Taxol and other microtubule-interactive agents
38. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization
39. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
40. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
41. 282 in β-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol
42. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer
43. p53 is associated with cellular microtubules and is transported to the nucleus by dynein
44. Modeling human lung cancer in mice: Similarities and shortcomings
45. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs
46. Tumour site, sex, and survival in colorectal cancer
47. p53 gene mutations are associated with shortened survival in patients with advanced non-small-cell lung cancer: An analysis of medically managed patients
48. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas
49. COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth and apoptosis
50. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma
51. Correlation of genetic instability with mismatch repair protein expression and p53 mutation in non-small-cell lung cancer
52. Prognostic implication of microsatellite alteration profiles in early-stage non-small-cell lung cancer
53. Microsatellite instability at selected tetranucleotide repeats is associated with mutations in non-small-cell lung cancer
54. How many tumor suppressor genes are involved in human lung carcinogenesis?
55. A 1.4-Mb high-resolution physical map and contig of chromosome segment 11p15.5 and genes in the LOH11A metastasis suppressor region
56. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1)
57. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line
58. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage
59. A novel molecular staging protocol for non-small cell lung cancer
60. Implications and prognostic value of K-ras mutations for early-stage lung cancer in women
61. Ras oncogene-induced sensitization to 1-β-D-arabinofuranosylcytosine
62. Oncogenic ras results in increased cell kill due to defective thermoprotection in lung cancer cells
63. Cell cycle and cancer
64. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small-cell lung cancer
65. Overexpression of cyclin B1 in early-stage non-small-cell lung cancer and its clinical implication
66. Prognostic significance of cyclin E overexpression in resected non-small-cell lung cancer
67. waf1/cip1 cyclin dependent kinase inhibitor gene: Association with human esophageal cancer
68. waf1/cip1 cyclin-dependent kinase inhibitor gene and human oral cancer
69. Expression of proliferating cell nuclear antigen and CD44 variant isoforms in the primary and metastatic sites of nonsmall cell lung carcinoma with intrapulmonary metastases
70. Heterogeneities in the biological and biochemical functions of Smad2 and Smad4 mutants naturally occurring in human lung cancers
71. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma
72. Altered HOX and WNT7A gene expression in human lung cancer
73. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas
74. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer
75. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer
76. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells
77. Genetic susceptibility associated with rare HRAS1 variable number of tandem repeats alleles in Spanish non-small-cell lung cancer patients
78. Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer
79. Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small-cell lung cancer